Author
Listed:
- Joanna Cyrta
(University of Bern
Weill Cornell Medicine)
- Anke Augspach
(University of Bern)
- Maria Rosaria Filippo
(University of Bern
University Hospital Basel, University of Basel)
- Davide Prandi
(University of Trento)
- Phillip Thienger
(University of Bern)
- Matteo Benelli
(University of Trento
Hospital of Prato)
- Victoria Cooley
(Weill Cornell Medicine)
- Rohan Bareja
(Weill Cornell Medicine
Weill Cornell Medicine)
- David Wilkes
(Weill Cornell Medicine)
- Sung-Suk Chae
(Weill Cornell Medicine)
- Paola Cavaliere
(Weill Cornell Medicine)
- Noah Dephoure
(Weill Cornell Medicine
Weill Cornell Medicine)
- Anne-Christine Uldry
(University of Bern)
- Sophie Braga Lagache
(University of Bern)
- Luca Roma
(University Hospital Basel, University of Basel)
- Sandra Cohen
(Weill Cornell Medicine)
- Muriel Jaquet
(University of Bern)
- Laura P. Brandt
(University of Bern)
- Mohammed Alshalalfa
(University of California at San Francisco)
- Loredana Puca
(Weill Cornell Medicine)
- Andrea Sboner
(Weill Cornell Medicine
Weill Cornell Medicine
Weill Cornell Medicine
Weill Cornell Medicine)
- Felix Feng
(University of Bern)
- Shangqian Wang
(Memorial Sloan-Kettering Cancer Center)
- Himisha Beltran
(Weill Cornell Medicine
Dana Farber Cancer Institute)
- Tamara Lotan
(Johns Hopkins University School of Medicine
Johns Hopkins University School of Medicine
Johns Hopkins University School of Medicine)
- Martin Spahn
(Prostate Center Bern
Essen University Hospital, University of Duisburg-Essen)
- Marianna Kruithof-de Julio
(University of Bern
University of Bern
Inselspital)
- Yu Chen
(Weill Cornell Medicine)
- Karla V. Ballman
(Weill Cornell Medicine)
- Francesca Demichelis
(Weill Cornell Medicine
University of Trento)
- Salvatore Piscuoglio
(University Hospital Basel, University of Basel
University of Basel
Clarunis Universitäres Bauchzentrum Basel)
- Mark A. Rubin
(University of Bern
Inselspital
Bern Center for Precision Medicine)
Abstract
Advanced prostate cancer initially responds to hormonal treatment, but ultimately becomes resistant and requires more potent therapies. One mechanism of resistance observed in around 10–20% of these patients is lineage plasticity, which manifests in a partial or complete small cell or neuroendocrine prostate cancer (NEPC) phenotype. Here, we investigate the role of the mammalian SWI/SNF (mSWI/SNF) chromatin remodeling complex in NEPC. Using large patient datasets, patient-derived organoids and cancer cell lines, we identify mSWI/SNF subunits that are deregulated in NEPC and demonstrate that SMARCA4 (BRG1) overexpression is associated with aggressive disease. We also show that SWI/SNF complexes interact with different lineage-specific factors in NEPC compared to prostate adenocarcinoma. These data point to a role for mSWI/SNF complexes in therapy-related lineage plasticity, which may also be relevant for other solid tumors.
Suggested Citation
Joanna Cyrta & Anke Augspach & Maria Rosaria Filippo & Davide Prandi & Phillip Thienger & Matteo Benelli & Victoria Cooley & Rohan Bareja & David Wilkes & Sung-Suk Chae & Paola Cavaliere & Noah Dephou, 2020.
"Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity,"
Nature Communications, Nature, vol. 11(1), pages 1-16, December.
Handle:
RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-19328-1
DOI: 10.1038/s41467-020-19328-1
Download full text from publisher
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Sukanya Panja & Mihai Ioan Truica & Christina Y. Yu & Vamshi Saggurthi & Michael W. Craige & Katie Whitehead & Mayra V. Tuiche & Aymen Al-Saadi & Riddhi Vyas & Shridar Ganesan & Suril Gohel & Frederic, 2024.
"Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC,"
Nature Communications, Nature, vol. 15(1), pages 1-24, December.
- Ni Li & Qiuli Liu & Ying Han & Siyu Pei & Bisheng Cheng & Junyu Xu & Xiang Miao & Qiang Pan & Hanling Wang & Jiacheng Guo & Xuege Wang & Guoying Zhang & Yannan Lian & Wei Zhang & Yi Zang & Minjia Tan , 2022.
"ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression,"
Nature Communications, Nature, vol. 13(1), pages 1-20, December.
- Marco Bolis & Daniela Bossi & Arianna Vallerga & Valentina Ceserani & Manuela Cavalli & Daniela Impellizzieri & Laura Di Rito & Eugenio Zoni & Simone Mosole & Angela Rita Elia & Andrea Rinaldi & Ricar, 2021.
"Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression,"
Nature Communications, Nature, vol. 12(1), pages 1-15, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-19328-1. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.